Evaluation of Targeted Alpha Therapy Using [²¹¹At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.

ABSTRACT: Triple-negative breast cancer (TNBC) presents limited therapeutic options and is associated with poor prognosis. Early detection and the development of novel therapeutic agents are therefore imperative. Fibroblast activation protein (FAP) is a membrane protein expressed on cancer-associated fibroblasts (CAFs) that plays an essential role in TNBC proliferation, migration, and invasion. Consequently, it is hypothesized that the Astatine (²¹¹At)-labeled FAP inhibitor (FAPI) selectively exerts anti-tumor effects through alpha-particle emission. In this study, we aimed to assess its theranostic capabilities by integrating [¹⁸F]FAPI-74 PET imaging with targeted alpha therapy using [²¹¹At]FAPI1 in TNBC models. Mice xenografts were established by transplanting MDA-

SUBMITTER: Abe K 

PROVIDER: S-EPMC11547022 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature